CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 13:40:18 2024-05-31 EDT | ||
| 8.87 EUR | +12.99% |
|
| Current month | +125.13% | ||
| 1 month | +125.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 8.87 | +12.99% |
| 24-05-30 | 7.85 | -3.80% |
| 24-05-29 | 8.16 | -4.45% |
| 24-05-28 | 8.54 | -12.77% |
| 24-05-27 | 9.79 | +3.60% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:40 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GFA |
| ISIN | DE000VU8GFA7 |
| Date issued | 2023-06-13 |
| Strike | 357.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.17 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.79 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.04 € |
| Spread % | 0.43% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
